Lixte Biotech Hlds (LIXT)

Mar 31, 2025, 8:30 AM EDT - 4 weeks ago

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Mar 27, 2025, 8:30 AM EDT - 4 weeks ago

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

Feb 25, 2025, 8:30 AM EST - 2 months ago

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

Feb 13, 2025, 10:35 AM EST - 2 months ago

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 11, 2025, 8:42 AM EST - 2 months ago

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 10, 2025, 5:00 PM EST - 2 months ago

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

Sep 4, 2024, 8:30 AM EDT - 8 months ago

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Aug 26, 2024, 8:30 AM EDT - 8 months ago

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Aug 19, 2024, 8:30 AM EDT - 9 months ago

LIXTE Biotechnology Provides Update On Recent Activities and Developments

Aug 15, 2024, 8:30 AM EDT - 9 months ago

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Aug 14, 2024, 10:50 PM EDT - 9 months ago

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

Jun 14, 2024, 11:00 AM EDT - 11 months ago

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

Jun 14, 2024, 9:30 AM EDT - 11 months ago

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Jun 6, 2024, 8:30 AM EDT - 11 months ago

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

Jun 3, 2024, 8:30 AM EDT - 11 months ago

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

May 20, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Provides Update on Recent Activities

May 8, 2024, 9:25 AM EDT - 1 year ago

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

Mar 21, 2024, 8:30 AM EDT - 1 year ago

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Feb 27, 2024, 8:30 AM EST - 1 year ago

Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

Feb 26, 2024, 8:30 AM EST - 1 year ago

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Jan 29, 2024, 8:30 AM EST - 1 year ago

First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

Nov 13, 2023, 8:30 AM EST - 1 year ago

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

Oct 9, 2023, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

Sep 26, 2023, 8:30 AM EDT - 1 year ago

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Sep 20, 2023, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

Jul 20, 2023, 4:05 PM EDT - 1 year ago

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

Jun 23, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Jun 7, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE's Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

Jun 2, 2023, 12:30 PM EDT - 2 years ago

LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023

May 30, 2023, 8:30 AM EDT - 2 years ago

Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology's Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy

Apr 24, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

Apr 4, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope's Ongoing Phase 1b Clinical Trial in Evaluating Lixte's Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer

Feb 14, 2023, 1:50 PM EST - 2 years ago

LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH

Feb 7, 2023, 12:16 PM EST - 2 years ago

LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

Nov 30, 2022, 8:05 AM EST - 2 years ago

LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference

Oct 13, 2022, 8:30 AM EDT - 2 years ago

LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP

Jun 21, 2022, 8:30 AM EDT - 3 years ago

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

Jun 15, 2022, 8:30 AM EDT - 3 years ago

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

May 2, 2022, 10:45 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru Joins

ATER VERU ZYME

Apr 14, 2022, 6:45 PM EDT - 3 years ago

LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

Apr 14, 2022, 2:54 PM EDT - 3 years ago

WallachBeth Capital Announces Completion of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct Offering

Apr 13, 2022, 9:00 AM EDT - 3 years ago

WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)

Apr 13, 2022, 8:30 AM EDT - 3 years ago

WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)

Apr 12, 2022, 1:53 PM EDT - 3 years ago

LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market

Apr 12, 2022, 9:32 AM EDT - 3 years ago

Lixte Biotech Shares Jumps Over 100% On Promising Preclinical Data From Lead Program In KRAS-Mutant Cancers

Apr 12, 2022, 8:30 AM EDT - 3 years ago

LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations

Mar 22, 2022, 8:30 AM EDT - 3 years ago

Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology's Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy

Mar 16, 2022, 8:30 AM EDT - 3 years ago

LIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor Conference

Jan 12, 2022, 8:30 AM EST - 3 years ago

Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100

Jan 5, 2022, 9:40 AM EST - 3 years ago

See Why Lixte Biotech Shares Trading At Over 100%?